Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide

Abstract EN

Previous studies showed associations between variants in TCF7L2 gene and the therapeutic response to sulfonylureas.

All sulfonylureas stimulate insulin secretion by the closure of ATP-sensitive potassium (KATP) channel.

The aim of the present study was to compare TCF7L2 genotype specific effect of gliclazide binding to KATP channel A-site (Group 1) with sulfonylureas binding to AB-site (Group 2).

A total of 101 patients were treated with sulfonylureas for 6 months as an add-on therapy to the previous metformin treatment.

TCF7L2 rs7903146 C/T genotype was identified by real-time PCR with subsequent melting curve analysis.

Analyses using the dominant genetic model showed significantly higher effect of gliclazide in the CC genotype group in comparison with combined CT + TT genotype group (1.32±0.15% versus 0.73±0.11%, Padj=0.005).

No significant difference in ΔHbA1c between the patients with CC genotype and the T-allele carriers was observed in Group 2.

In the multivariate analysis, only the TCF7L2 genotype (P=0.006) and the baseline HbA1c (P<0.001) were significant predictors of ΔHbA1c.

After introducing an interaction term between the TCF7L2 genotype and the sulfonylurea type into multivariate model, the interaction became a significant predictor (P=0.023) of ΔHbA1c.

The results indicate significantly higher difference in ΔHbA1c among the TCF7L2 genotypes in patients treated with gliclazide than in patients treated with glimepiride, glibenclamide, or glipizide.